SCHEMBL1699428

SCHEMBL1699428

CCOC(=O)C(OCc1ccc(OC)cc1)c1c(C)cc2cc(Br)ccc2c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
KMT2A Q03164 6/20 0.36
ALDH1A1 P00352 4/20 0.36
LMNA P02545 4/20 0.36
MEN1 O00255 4/20 0.36
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36
HSP90AA1 P07900 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAOB P27338 3/20 0.36
RXFP1 Q9HBX9 2/20 0.35
MAOA P21397 2/20 0.35
EPHX2 P34913 1/20 0.35
PLG P00747 2/20 0.34
KLK1 P06870 2/20 0.34
KLK6 Q92876 2/20 0.34
HPGD P15428 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272103 0.92 MAPT (0.39) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL1699312 0.88 ALOX15 (0.39) KMT2AALDH1A1LMNAMEN1SMN1; SMN2
SCHEMBL1699498 0.87 PSEN1 (0.44) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL1699478 0.83 CCR2 (0.39) KMT2AALDH1A1LMNAMEN1POLB
SCHEMBL1699600 0.81 MEN1 (0.40) MAPTKMT2AALDH1A1MEN1PLG
SCHEMBL1699290 0.79 L3MBTL1 (0.38) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL15099653 0.78 TBK1 (0.38) MAPTALDH1A1LMNASMN1; SMN2RXFP1
SCHEMBL1699727 0.78 CCR2 (0.41) MAPTKMT2AMEN1KDM4EMAOB
SCHEMBL16657255 0.77 ALDH1A1 (0.39) MAPTALDH1A1LMNAPOLBSMN1; SMN2
SCHEMBL15093489 0.77 ALDH1A1 (0.39) MAPTALDH1A1LMNAPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588450-B1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES INC (US) 2017-05-24 EP disclosed
EP-2588450-B1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES INC (US) 2017-05-24 EP disclosed
US-9102614-B2 Naphth-2-ylacetic acid derivatives to treat AIDS GILEAD SCIENCES, INC. (US) 2015-08-11 US disclosed
US-9102614-B2 Naphth-2-ylacetic acid derivatives to treat AIDS GILEAD SCIENCES, INC. (US) 2015-08-11 US disclosed
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
EP-2588450-A1 NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS Gilead Sciences, Inc. (US) 2013-05-08 EP disclosed
WO-2012003497-A1 NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed
WO-2012003497-A1 NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS NFATC1, AADAT, ACAT1 MAPT 280/4885KMT2A 375/4885ALDH1A1 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.